Baymatob Operations Pty. Ltd news
Sydney medical device company Baymatob has completed a placement of $4.215 million, with proceeds used to continue in-human clinical trials for its AI-guided labour monitoring device, Oli.
Cornerstoned by Australian Unity’s Future of Healthcare Fund, the placement was strongly supported by Australian institutional and high net worth investors, securing long-term capital partners to support Baymatob’s ongoing clinical development and path to commercialisation.
Found
Baymatob™, a pioneer in women’s health and AI-guided monitoring for pregnancy and labour, is preparing for an exciting growth stage. In anticipation and support of this growth Dr Sarah McDonald has been appointed Chief Visionary Officer and Founder, and Tony Barclay has been appointed Chair of the Board.
Sarah is the founder of Baymatob and has held the role of both CEO and Chair for the company. As an inventor of Oli, after the traumatic birth experience of her own child
Baymatob™, a pioneer in women’s health and AI-guided monitoring for maternity and child birth, is excited to announce the appointment of Dr Sarah McDonald as Chair of the Board, Tara Croft as Chief Executive Officer, and Tony Barclay as Acting Chief Financial Officer.
Sarah is the founder of Baymatob and as CEO has worked to establish and grow the company over the last eight years. She is an inventor of Oli, Baymatob’s AI-guided maternity sensor, monitoring and
BaymatobTM, a MedTech company founded by a Sydney mother after her own traumatic birth experience, has developed a world-first labour monitoring device that has achieved US Food and Drug Administration (FDA) Breakthrough Device Designation. This sets Baymatob’s game changing maternal diagnostic tool called OliTM on an streamlined and supported path toward regulatory approval.
Oli seeks to identify an individual, during labour, who is at hi
Today the Ingham Institute launched their centre for Robotics and Health Technology from the BaymatobTM premises. The Institute is one of the only in Australia to combine clinical expertise with commercial partnerships to oversee the life cycle of bringing life-saving treatments to market – from concepts to clinical trials to commercialisation and introduction into the healthcare systems. The event was a fantastic success attended by a number of individuals